Shkreli Daraprim price U-turn prompts renewed fury
November 26, 2015Medical Communications, Research and Development, Sales and Marketing
Turing CEO Martin Shkreli has sparked yet more criticism, after going back on a pledge to cut the price of …
Companies face mixed fortunes in ultra-orphan approvals
November 26, 2015Medical Communications, Research and Development BioMarin, Duchenne Muscular Dystrophy, FDA, Genzyme, NICE, ultra-orphan drugs
UK regulator NICE has recommended Vimizin, a drug for a very rare genetic disorder, after the manufacturer and NHS England …
GSK begins Phase III study of sirukumab in giant cell arteritis
November 26, 2015Business Services, Research and Development, Sales and Marketing GSK, Janssen
GSK today announced it has begun a Phase III study evaluating sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the …
Shire prepares new Baxalta bid
November 26, 2015Business Services, Sales and Marketing
Following rejection in an earlier bid, it has emerged that Shire is preparing a new takeover offer for US biotech …
Lilly cancer drug gets US approval
November 26, 2015NSCLC, Portrazza, lilly, lung cancer, necitumumab, non-small cell lung cancer, oncology
Eli Lilly has received FDA approval for its monoclonal antibody Portrazza, in combination with gemcitabine and cisplatin, for patients with …
Trump and Clinton hit out at Pfizer over tax inversion plan
November 25, 2015Sales and Marketing Allergan, Pfizer
Politicians on both sides of the US spectrum have criticised Pfizer over its $160 billion buyout of Allergan and its …
UK Spending Review: science budget protected, NHS gets £10 billion boost
November 25, 2015Research and Development
Feared 40% cuts to the UK’s science budget failed to materialise today, as Chancellor George Osborne announced the budget would …
Challenges in oncology R&D – part 2
November 25, 2015Manufacturing and Production, Research and Development R&D, Takeda, oncology
Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …
BMS and Medicines Patent Pool collaborate to increase Hep C medicine access
November 25, 2015Manufacturing and Production, Research and Development Bristol-Myers Squibb, Medicines Patent Pool, daclatasvir, daklinza, hepatitis C
The Medicines Patent Pool (MPP) has announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers …
Teva and Heptares enter $400m agreement for small-molecule migraine treatment
November 25, 2015Research and Development Heptares, Teva, collaboration, migraine
Teva Pharmaceuticals and Heptares Therapeutics have signed a licensing and drug-discovery agreement for Teva to gain exclusive global rights to …
UK commits £150 million to new Dementia Research Institute
November 25, 2015Research and Development dementia. R&D
The UK government has launched plans for a new £150 million dementia research institute that it says will drive a …
Bristol-Myers Squibb in new oncology collaboration
November 25, 2015Research and Development Bristol-Myers Squibb, collaboration, immuno-oncology, investment, venture capital
Bristol-Myers Squibb and European healthcare fund Life Sciences Partners are forming a strategic collaboration to identify breakthrough technologies. The companies …
PlaqueTec appoints Dr Nick West as CMO
November 24, 2015Research and Development PlaqueTec
PlaqueTec has appointed Dr Nick West as its new chief medical officer. Dr West is a research-active clinician with extensive …
FDA approves BMS’s Opdivo for renal cell carcinoma
November 24, 2015Research and Development
The FDA has approved Bristol Myers Squibb’s immunotherapy Opdivo for the treatment of patients with advanced renal cell carcinoma (RCC). …
Genmab pulls plug on Phase III Arzerra trial
November 24, 2015Manufacturing and Production, Research and Development Arzerra, Genmab, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma, ofatumumab, phase III, phase III failure
Genmab has stopped a Phase III study of its CD20-directed monoclonal antibody Arzerra, after it was shown to be unlikely …
Construction for new £55m cell and gene manufacturing centre in Stevenage begins
November 24, 2015Manufacturing and Production Catapult, Cell Therapy Catapult, Hertfordshire, gene therapy, manufacturing, stevenage
The Government-backed Cell Therapy Catapult has begun the construction for its cell and gene therapy manufacturing centre. The construction …
FDA approves Beximco to manufacture Carvedilol for US
November 24, 2015Manufacturing and Production Bangladesh, Beximco, Carvediol, FDA, exports, generics
Beximco Pharmaceuticals has become the first Bangladeshi pharma company to receive approval for a prescription drug to be manufactured in …
Novartis and Amgen drugs signed-off by European Commission
November 24, 2015Manufacturing and Production Amgen, Entresto, European Commission, Novartis, blincyto
The European governing body, the European Commission, has approved the Novartis drug Entresto for heart failure and Amgen’s Blincyto for …
Novo Nordisk to go green by 2020
November 24, 2015Manufacturing and Production Novo Nordish, manufacturing, production, renewable energy
Novo Nordisk has announced plans to go green in the next five years by using only electricity from renewable sources …
OmniaMed UK appoints new senior management
November 24, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
OmniaMed has strengthened its senior management team by appointing Dr Clive Deverson as managing director and Dr Colin Griffin as …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
